



Poster Session 4: Friday, February 25: 2:35 pm – 3:00 pm MT

Abstract	Screen	Order	Abstract Title	Presenter
153	1	1	Differential Activation of Cancer-Associated Fibroblasts in HPV-Associated Head and Neck Squamous Cell Carcinoma Patients Detected Using Spatial Transcriptomics	Sarah Sussman
154	1	2	Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)	Terrence Fisher
155	2	1	A phase 2/3, randomized, open-label study of bempegaldesleukin plus pembrolizumab versus pembrolizumab alone in first-line treatment of patients with metastatic or recurrent head and neck squamous cell carcinoma with PD-L1-expressing tumors (PROPEL-36)	Robert Haddad
156	2	2	Lachnoclostridium and Immune Inflamed Gene Expression Signature Association in Head&Neck Cancers	Emrullah Yilmaz
157	3	1	Preliminary Safety of PDS0101 (Versamune +HPVmix) and Pembrolizumab Combination Therapy in Subjects with Recurrent/Metastatic Human Papillomavirus-16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Jared Weiss
158	3	2	Impact of Tobacco, Marijuana and Alcohol Use on Overall Survival in Recurrent Metastatic Head and Neck Cancer Patients Treated With Immune Checkpoint Inhibitors	Majd Issa
159	4	1	Immunotherapy Response in Cutaneous Squamous Cell Carcinoma Patients With Cranial Nerve Involvement	Nerea Lopetegui
161	5	1	Immunotherapy Response in Patients with Pre-Existing Autoimmune Disorders and Head and Neck Cancers	Catherine Han
162	5	2	Outcomes Following Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Experience	Anirudh Yalamanchali
163	6	1	Role of Tertiary Lymphoid Structures and Immunotherapy in Head & Neck Squamous Cell Carcinoma	Paavali Hannikainen
174	6	2	Immune and Tumor Genome Signatures Associated With Response to Radiotherapy and Chk-1 Inhibition in a Phase 1b Clinical Trial for Patients with Head and Neck Squamous Cell Carcinoma	Curtis Clark
175	7	1	Evaluating the Therapeutic Potential of a Small Molecule ATR Inhibitor Combined with Radiotherapy for Head and Neck Squamous Cell Carcinoma	Yvonne Mowery
176	7	2	HPV16-A1 Genotype is Associated with Poor Recurrence-Free Survival in HPV16 Associated Squamous Cell Carcinoma of the Oropharynx	Travis Schrank
177	8	1	Decreased Expression of PTENP1 by Smoking Induces Drug Resistance through c-MYC Activation in HPV+ Oropharyngeal Squamous Cell Carcinoma	Zixing Liu
178	8	2	Detection of Locoregional Minimal Residual Disease Immediately after Surgery through Multi-omic Analysis of Tumor-associated Cell-Free DNA in Surgical Drain Fluid	Noah Earland
179	9	1	Stable Reconstitution of Gasdermin-E in a Gasdermin-E-Deficient Head and Neck Squamous Cell Carcinoma Mouse Cell Line Enhances Pyroptosis-Mediated Release of Tumor Immunogenic Molecules	Angela Alnemri
180	9	2	Antitumor Activity of Tipifarnib and PI3K Pathway Inhibitor in HRAS-associated HNSCC	Alison Smith
181	10	1	A Phase 0 Master Protocol Utilizing a Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Drug Combinations in Patients with Solid Tumors	Thomas Ow
182	10	2	Targeting PI3K α/δ and the ErbB family of protein-tyrosine kinases in cisplatin-resistant head and neck squamous cell carcinomas	Hancai Dan